DFTX Definium Therapeutics, Inc. - Common Shares

NASDAQ · · View on SEC EDGAR ↗
$45.80
Price · Aug 19, 2026
Fundamentals as of Aug 6, 2026
52W Range
$9–$50
90% of range
Analyst Rating
BUY
23 analysts
Price Target
$67
+46% upside
P/E (TTM)
-22.2
ROE
-71.0%
Net Profit Margin
—

About Definium Therapeutics, Inc. - Common Shares Company overview from Wikipedia

Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.

Read more

Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.

History

MindMed was founded in May 2019 by Stephen Hurst and Jamon Rahn.

MindMed initially focused on developing treatments for opioid withdrawal and opioid use disorder with 18-MC, a non-hallucinogenic molecule based on the psychoactive alkaloid ibogaine. In June 2019, it acquired the 18-MC drug development program, previously funded by the National Institute on Drug Abuse, and in September began to prepare 18-MC for a Phase I FDA clinical trial to enable further clinical trials targeting opioid withdrawal and opioid use disorder.

MindMed was the first psychedelic pharmaceutical company to go public, listing on the Canadian NEO Exchange in March of 2020 through a reverse takeover with the Canadian gold mining company Broadway Gold Mining. It began trading on the Nasdaq as MNMD in April 2021 after being approved for an uplisting from the OTC Markets.

In a press release on June 9, 2021 MindMed announced that Jamon Rahn was stepping down both as the CEO and as a director on the board, to be replaced by then CDO Robert Barrow.

On February 26, 2021, MindMed closed its acquisition of digital health startup HealthMode. In connection with the acquisition, Daniel Karlin MD, CEO of HealthMode, was appointed to the position of CMO of the company.

On August 25, 2022, the first patient was dosed in a phase 2b trial for treatment of MM120 (now DT120) in generalized anxiety disorder (GAD). The study would go on to recruit 198 participants. The majority of trial participants experienced statistically significant improvements in their GAD scores, leading to the approval of multiple phase three human trials.

On January 12, 2026, MindMed rebranded to Definium Therapeutics.

Research

In March 2020, MindMed announced that it had partnered with NYU Langone to launch a clinical training program to train psychiatrists in psychedelic therapies and research to advance and deploy psychedelic medicines. The company committed $5 million to establish the center, which will also explore 18-MC and the use of drugs, including psilocybin-assisted therapy for alcohol use disorder.

In April 2020, the company entered into a long-term partnership with University Hospital Basel's Liechti Lab, gaining rights to more than ten years of the lab's data related to LSD, MDMA, and other psychedelic substances. The development of a novel compound designed to shorten the duration or stop an LSD experience that would allow LSD to be more widely used in a therapeutic environment was subsequently announced. Later that year a clinical trial studying the effects of DMT, the primary psychoactive ingredient in ayahuasca, and clinical trials combining MDMA and LSD were announced. A study to better understand and compare the altered states of consciousness induced by psilocybin and LSD began in August 2020,

and in October a Phase 1 study at the Liechti Lab on the acute dose dependent effects of LSD was completed. The results of the study were published by the American College of Neuropsychopharmacology in the journal Neuropsychopharmacology. In September 2021, further results were presented by Matthias Liechti, head of the Liechti Lab, at the INSIGHT Conference in Berlin. The results included the first clinical evidence on the comparative effects of LSD and psilocybin, stating 100mcg of LSD produced the same acute perceptual effects as a dose of 20 mg of psilocybin in healthy volunteers. Additionally, psilocybin taken after administering antidepressants for two weeks prior, was deemed safe, as well as reduced anxiety and blood pressure without hindering the psychedelic experience.

In December 2020, MindMed entered into an investigator-sponsored study agreement with Maastricht University in the Netherlands. The university provided facilities and personnel for a Phase 1 study to evaluate the effects of two low doses of LSD on mood, sleep and neuroplasticity.

In March 2024, the FDA granted breakthrough therapy designation to MindMed's form of LSD (MM120; now DT120) for the treatment of generalized anxiety disorder. This decision was influenced by a drug trial in which approximately half of the participants experienced significant relief from their symptoms. Positive results in clinical trials against general depression symptoms and generalized anxiety disorder were reported in 2026.

=== Ongoing clinical trials ===

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

DFTX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$45.80
Market Cap
$4.52B
P/E (TTM)
-22.2
EPS (TTM)
$-2.06
Revenue (TTM)
—
Div Yield
—
ROE
-71.0%
Debt/Equity
0.1
52W Range
$9 – $50

DFTX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income —
EPS $-2.06
5-point trend, +39.4%
2021-12-31 → 2025-12-31
Free Cash Flow —
Margins —

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
DFTX
Peer Median
P/E (TTM)
2-point trend, -43.8%
-22.2
30.7
P/S (TTM)
2-point trend, +153.0%
1098.6
3.4
P/B
2-point trend, +83.8%
13.6
3.9
EV / EBITDA
2-point trend, -119.6%
-25.0
—

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
DFTX
Peer Median
ROA
5-point trend, +34.7%
-49.5%
-16.2%
ROE
5-point trend, -20.5%
-71.0%
-21.5%
ROIC
2-point trend, +27.0%
-44.6%
—

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
DFTX
Peer Median
Debt / Equity
3-point trend, -32.5%
0.1
—
Current Ratio
5-point trend, -52.3%
6.3
4.5
Quick Ratio
5-point trend, -51.9%
6.2
—

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
DFTX
Peer Median
Revenue YoY
212.0%
—

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
DFTX
Peer Median
EPS (Diluted)
5-point trend, +39.4%
$-2.06
—

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
DFTX
Peer Median

DFTX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 23 analysts
  • Strong Buy 8 34.8%
  • Buy 14 60.9%
  • Hold 1 4.3%
  • Sell 0 0.0%
  • Strong Sell 0 0.0%

12-Month Price Target

16 analysts · 2026-08-16
Median target $66.00 +44.1%
Mean target $67.00 +46.3%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
-0.23%
Period EPS Actual EPS Est Surprise
June 30, 2026 $-1.44 $-0.56 -0.88%
March 31, 2026 $-0.71 $-0.50 -0.21%
Dec. 31, 2025 $-0.50 $-0.50 -0.00%
Sept. 30, 2025 $-0.78 $-0.51 -0.27%
June 30, 2025 $-0.50 $-0.37 -0.13%
March 31, 2025 $-0.27 $-0.37 0.10%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
DFTX $1.32B -6.5 212.0% — -71.0% —
AXSM $9.29B -49.6 65.5% -28.7% -227.0% —
CRNX $4.45B -9.4 640.7% -6046.2% -43.0% —
LQDA $3.01B -43.1 1031.2% -43.5% -230.0% —
BLTE — — — — — —
AMRX — 57.3 8.1% 2.4% -80.0% 36.9%
LGND $3.74B 30.8 60.4% 46.4% 13.5% —
EWTX $2.64B -15.2 — — -30.2% —
MANE — — — — 82.6% —
INDV — 21.9 4.3% 17.0% -118.3% 80.2%
LLY — 46.8 44.7% 31.7% 101.2% —

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 14
Annual Income Statement data for DFTX
Metric Trend 202520242023202220212020
R&D Expense 6-point trend, +531.6% $118M $65M $52M $36M $35M $19M
SG&A Expense 6-point trend, +237.8% $49M $39M $42M $30M $59M $14M
Operating Expenses 6-point trend, +403.5% $166M $104M $94M $66M $94M $33M
Operating Income 6-point trend, -403.5% $-166M $-104M $-94M $-66M $-94M $-33M
Interest Expense 3-point trend, +495.9% $5M $2M $920.0K · · ·
Other Non-op 6-point trend, -1827.7% $-17M $-5M $-2M $10M $-339.0K $-907.0K
Pretax Income 6-point trend, -441.6% $-184M $-109M $-96M $-57M $-94M $-34M
Income Tax 2-point trend, +100.0% $0 · · · $-1M ·
Net Income 6-point trend, -441.6% $-184M $-109M $-96M $-57M $-93M $-34M
EPS (Basic) 5-point trend, +39.4% $-2.06 $-1.54 $-2.44 $-1.84 $-3.40 ·
EPS (Diluted) 5-point trend, +39.4% $-2.06 $-1.54 $-2.44 $-1.84 $-3.40 ·
Shares (Basic) 5-point trend, +226.3% 89,327,608 70,461,067 39,157,420 30,857,463 27,377,082 ·
Shares (Diluted) 5-point trend, +226.3% 89,327,608 70,461,067 39,157,420 30,857,463 27,377,082 ·
EBITDA 5-point trend, -77.2% $-166M $-104M $-94M $-66M $-94M ·
Balance Sheet 20
Annual Balance Sheet data for DFTX
Metric Trend 202520242023202220212020
Cash & Equivalents 6-point trend, +221.9% $258M $274M $100M $142M $134M $80M
Short-term Investments 2-point trend, +153756000.00 $154M $0 · · · ·
Prepaid Expense 6-point trend, +442.2% $8M $8M $4M $4M $4M $1M
Current Assets 6-point trend, +414.4% $419M $282M $104M $146M $137M $82M
Goodwill 6-point trend, +19918000.00 $20M $20M $20M $20M $20M $0
Intangibles 4-point trend, -100.0% · $0 $527.0K $4M $7M ·
Other Non-current Assets 4-point trend, +160.4% $862.0K $613.0K $224.0K $331.0K · ·
Total Assets 6-point trend, +439.9% $440M $302M $125M $170M $164M $82M
Accounts Payable 6-point trend, +164.4% $5M $2M $4M $2M $4M $2M
Accrued Liabilities 6-point trend, +1973.6% $20M $13M $12M $6M $6M $986.0K
Current Liabilities 6-point trend, +2117.4% $67M $39M $32M $18M $10M $3M
Other Non-current Liabilities 4-point trend, -74.3% $496.0K · $32.0K $1M $2M ·
Total Liabilities 6-point trend, +1807.1% $108M $61M $46M $19M $12M $6M
Total Debt 3-point trend, +187.2% $41M $22M $14M · · ·
Common Stock · · $0 · · ·
Retained Earnings 6-point trend, -1205.4% $-583M $-399M $-290M $-194M $-138M $-45M
AOCI 6-point trend, +282.0% $1M $819.0K $343.0K $627.0K $1M $284.0K
Stockholders' Equity 6-point trend, +338.0% $332M $241M $78M $151M $152M $76M
Liabilities + Equity 6-point trend, +439.9% $440M $302M $125M $170M $164M $82M
Shares Outstanding 5-point trend, +251.2% 98,776,265 75,100,763 41,101,303 37,979,136 28,126,414 ·
Cash Flow 9
Annual Cash Flow data for DFTX
Metric Trend 202520242023202220212020
Deferred Tax · · · · $-1M ·
Amort. of Intangibles 6-point trend, +0.00 $0 $527.0K $3M $3M $3M $0
Operating Cash Flow 6-point trend, -457.5% $-132M $-79M $-64M $-50M $-46M $-24M
Investing Cash Flow 3-point trend, -50945.8% $-152M $0 · · $-297.0K ·
Stock Issued 6-point trend, -100.0% $0 $984.0K $8M $42M $82M $72M
Net Stock Activity 5-point trend, -100.0% $0 $984.0K $8M $42M $82M ·
Financing Cash Flow 6-point trend, +176.4% $267M $253M $22M $59M $99M $97M
Net Change in Cash 6-point trend, -121.7% $-16M $174M $-42M $9M $53M $73M
Taxes Paid $0 · · · · ·
Profitability 7
Annual Profitability data for DFTX
Metric Trend 202520242023202220212020
Operating Margin 3-point trend, -107.7% · · -2012.6% -4436.9% 26143.2% ·
Net Margin 3-point trend, -107.9% · · -2052.6% -3799.1% 25915.3% ·
Pretax Margin 3-point trend, -107.8% · · -2052.6% -3799.1% 26237.6% ·
EBITDA Margin 3-point trend, -107.7% · · -2012.6% -4436.9% 26143.2% ·
ROA 5-point trend, +34.7% -49.5% -50.9% -65.0% -34.0% -75.8% ·
ROE 5-point trend, -20.5% -71.0% -43.2% -110.0% -37.3% -58.9% ·
ROIC 2-point trend, +27.0% -44.6% · · · -61.1% ·
Liquidity & Solvency 5
Annual Liquidity & Solvency data for DFTX
Metric Trend 202520242023202220212020
Current Ratio 5-point trend, -52.3% 6.3 7.2 3.2 8.2 13.2 ·
Quick Ratio 5-point trend, -51.9% 6.2 7.0 3.1 7.9 12.8 ·
Debt / Equity 3-point trend, -32.5% 0.1 0.1 0.2 · · ·
LT Debt / Equity 3-point trend, -32.5% 0.1 0.1 0.2 · · ·
Interest Coverage 2-point trend, +33.3% -30.3 -45.5 · · · ·
Efficiency 1
Annual Efficiency data for DFTX
Metric Trend 202520242023202220212020
Asset Turnover 3-point trend, +1193.1% · · 0.0 0.0 -0.0 ·
Per Share 5
Annual Per Share data for DFTX
Metric Trend 202520242023202220212020
Book Value / Share 4-point trend, -15.3% $3.36 $3.21 $1.90 $3.97 · ·
Revenue / Share 2-point trend, +146.1% · · $0.12 $0.05 · ·
Cash Flow / Share 4-point trend, +9.4% $-1.47 $-1.12 $-1.64 $-1.62 · ·
Cash / Share 4-point trend, -30.3% $2.61 $3.65 $2.43 $3.74 · ·
EPS (TTM) 5-point trend, +39.4% $-2.06 $-1.54 $-2.44 $-1.84 $-3.40 ·
Growth Rates 1
Annual Growth Rates data for DFTX
Metric Trend 202520242023202220212020
Revenue YoY · · 212.0% · · ·
Valuation (TTM) 12
Annual Valuation (TTM) data for DFTX
Metric Trend 202520242023202220212020
Revenue TTM 5-point trend, +1247.1% $4M $4M $5M $1M $-359.0K ·
Net Income TTM 5-point trend, -97.6% $-184M $-109M $-96M $-57M $-93M ·
Market Cap 2-point trend, +153.0% $1.32B $523M · · · ·
Enterprise Value 2-point trend, +251.4% $952M $271M · · · ·
P/E 2-point trend, -43.8% -6.5 -4.5 · · · ·
P/S 2-point trend, +153.0% 321.2 126.9 · · · ·
P/B 2-point trend, +83.8% 4.0 2.2 · · · ·
P / Tangible Book 2-point trend, +79.4% 4.2 2.4 · · · ·
P / Cash Flow 2-point trend, -52.2% -10.1 -6.6 · · · ·
EV / EBITDA 2-point trend, -119.6% -5.7 -2.6 · · · ·
EV / Revenue 2-point trend, +251.4% 231.1 65.8 · · · ·
Earnings Yield 2-point trend, +30.5% -15.4% -22.1% · · · ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement
2025-12-312024-12-312023-12-312022-12-312021-12-31
Operating Margin % ——-2012.6%-4436.9%26143.2%
Net Income $-184M$-109M$-96M$-57M$-93M
Diluted EPS $-2.06$-1.54$-2.44$-1.84$-3.40
Balance Sheet
2025-12-312024-12-312023-12-312022-12-312021-12-31
Debt / Equity 0.10.10.2——
Current Ratio 6.37.23.28.213.2
Quick Ratio 6.27.03.17.912.8

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 387 filers · $4.0B total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
167 28 108 69 —

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.

Institution Value Shares % of tracked 13F Type
Avoro Capital Advisors LLC $338,165,292 7,188,888 8.35% Shares
Driehaus Capital Management LLC $322,001,783 6,845,276 7.95% Shares
Capital World Investors $252,497,690 5,367,723 6.24% Shares
FMR LLC $188,434,384 4,005,833 4.65% Shares
GEODE CAPITAL MANAGEMENT, LLC $148,941,987 3,165,629 3.68% Shares
STATE STREET CORP $144,195,946 3,065,390 3.56% Shares
Capital International Investors $139,398,806 2,963,410 3.44% Shares
Octagon Capital Advisors LP $138,768,000 2,950,000 3.43% Shares
Deep Track Capital, LP $129,360,000 2,750,000 3.20% Shares
WELLINGTON MANAGEMENT GROUP LLP $104,294,124 2,217,137 2.58% Shares
Commodore Capital LP $94,080,000 2,000,000 2.32% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $77,541,959 1,648,426 1.92% Shares
RA CAPITAL MANAGEMENT, L.P. $70,560,000 1,500,000 1.74% Shares
VANGUARD CAPITAL MANAGEMENT LLC $69,922,796 1,486,454 1.73% Shares
Siren, L.L.C. $66,772,951 1,419,493 1.65% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $65,216,256 1,386,400 1.61% Call option
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $50,971,415 1,083,576 1.26% Shares
GOLDMAN SACHS GROUP INC $49,226,937 1,046,491 1.22% Shares
Woodline Partners LP $47,211,273 1,003,641 1.17% Shares
ADAGE CAPITAL PARTNERS GP, L.L.C. $47,040,000 1,000,000 1.16% Shares
Boxer Capital Management, LLC $46,969,440 998,500 1.16% Shares
CITADEL ADVISORS LLC $43,623,579 927,372 1.08% Shares
TWO SIGMA INVESTMENTS, LP $43,362,319 921,818 1.07% Shares
Balyasny Asset Management L.P. $42,217,365 897,478 1.04% Shares
AMERIPRISE FINANCIAL INC $41,156,144 874,918 1.02% Shares
VANGUARD FIDUCIARY TRUST CO $38,934,679 827,693 0.96% Shares
Holocene Advisors, LP $37,470,841 796,574 0.93% Shares
AWM Investment Company, Inc. $36,916,992 784,800 0.91% Shares
Polar Capital Holdings Plc $36,561,981 777,253 0.90% Shares
ALLIANCEBERNSTEIN L.P. $34,082,124 1,803,287 0.84% Shares
EVENTIDE ASSET MANAGEMENT, LLC $33,398,400 710,000 0.82% Shares
Qube Research & Technologies Ltd $32,123,663 682,901 0.79% Shares
NEUBERGER BERMAN GROUP LLC $29,068,697 617,957 0.72% Shares
Candriam S.C.A. $28,874,744 614,425 0.71% Shares
ArrowMark Colorado Holdings LLC $26,533,806 564,069 0.66% Shares
Catalio Capital Management, LP $26,468,091 562,672 0.65% Shares
Blackstone Inc. $26,418,228 561,612 0.65% Shares
Integral Health Asset Management, LLC $25,872,000 550,000 0.64% Shares
BAMCO INC /NY/ $24,465,880 520,108 0.60% Shares
FRANKLIN RESOURCES INC $22,871,742 486,219 0.56% Shares
Point72 Asset Management, L.P. $22,766,419 483,980 0.56% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $22,155,840 471,000 0.55% Put option
Ensign Peak Advisors, Inc $21,925,626 466,106 0.54% Shares
GREAT POINT PARTNERS LLC $19,992,000 425,000 0.49% Shares
JANE STREET GROUP, LLC $19,940,256 423,900 0.49% Call option
RTW INVESTMENTS, LP $18,816,000 400,000 0.46% Shares
SILVERARC CAPITAL MANAGEMENT, LLC $18,816,000 400,000 0.46% Shares
Cormorant Asset Management, LP $18,816,000 400,000 0.46% Shares
Ally Bridge Group (NY) LLC $18,816,000 400,000 0.46% Call option
ASSETMARK, INC $18,653,336 396,542 0.46% Shares
MARSHALL WACE, LLP $18,196,013 386,820 0.45% Shares
Caption Management, LLC $17,503,584 372,100 0.43% Call option
ORBIMED ADVISORS LLC $17,188,416 365,400 0.42% Shares
JANE STREET GROUP, LLC $15,415,008 327,700 0.38% Put option
SILVERBACK ASSET MANAGEMENT LLC $13,848,576 294,400 0.34% Call option
CITADEL ADVISORS LLC $13,547,520 288,000 0.33% Call option
Tetragon Partners GP Ltd $13,500,010 286,990 0.33% Shares
CITADEL ADVISORS LLC $13,382,880 284,500 0.33% Put option
MILLENNIUM MANAGEMENT LLC $12,516,215 266,076 0.31% Shares
Sofinnova Investments, Inc. $12,037,677 255,903 0.30% Shares
PFM Health Sciences, LP $11,713,901 249,020 0.29% Shares
HighVista Strategies LLC $11,425,263 242,884 0.28% Shares
Trexquant Investment LP $10,969,681 233,199 0.27% Shares
SEVEN GRAND MANAGERS, LLC $10,584,000 225,000 0.26% Shares
Swiss National Bank $10,405,248 221,200 0.26% Shares
Eversept Partners, LP $10,216,382 217,185 0.25% Shares
TD Asset Management Inc $9,852,998 209,460 0.24% Shares
ROYCE & ASSOCIATES LP $9,810,239 208,551 0.24% Shares
SEB Asset Management AB $9,796,249 208,254 0.24% Shares
SUPERSTRING CAPITAL MANAGEMENT LP $8,856,785 188,282 0.22% Shares
EMERALD ADVISERS, LLC $8,408,447 178,751 0.21% Shares
Aberdeen Group plc $8,232,000 175,000 0.20% Shares
Tri Locum Partners LP $7,667,332 162,996 0.19% Shares
RHUMBLINE ADVISERS $7,436,824 158,096 0.18% Shares
Bank of New York Mellon Corp $7,078,203 150,472 0.17% Shares
Seven Fleet Capital Management LP $6,992,355 148,647 0.17% Shares
MANUFACTURERS LIFE INSURANCE COMPANY, THE $6,885,151 146,368 0.17% Shares
Brevan Howard Capital Management LP $6,750,146 143,498 0.17% Shares
Rock Springs Capital Management LP $6,735,516 143,187 0.17% Shares
SummitTX Capital, L.P. $6,702,683 142,489 0.17% Shares
STEMPOINT CAPITAL LP $6,450,313 137,124 0.16% Shares
BIT Capital GmbH $6,027,282 128,131 0.15% Shares
FRED ALGER MANAGEMENT, LLC $5,892,042 125,256 0.15% Shares
BlackRock, Inc. $5,861,090 124,598 0.14% Shares
BANK OF AMERICA CORP /DE/ $5,747,818 122,190 0.14% Shares
AdvisorShares Investments LLC $5,709,762 121,381 0.14% Shares
EMERALD MUTUAL FUND ADVISERS TRUST $5,703,553 121,249 0.14% Shares
Informed Momentum Co LLC $5,688,453 120,928 0.14% Shares
Schonfeld Strategic Advisors LLC $5,626,452 119,610 0.14% Shares
ALPS ADVISORS INC $5,192,652 110,388 0.13% Shares
MILLENNIUM MANAGEMENT LLC $5,174,400 110,000 0.13% Put option
Russell Investments Group, Ltd. $4,987,933 106,036 0.12% Shares
Data Collective IV GP, LLC $4,720,464 100,350 0.12% Shares
Burkehill Global Management, LP $4,704,000 100,000 0.12% Shares
BNP PARIBAS FINANCIAL MARKETS $4,539,830 96,510 0.11% Shares
KEYSTONE INVESTORS PTE LTD $4,473,504 95,100 0.11% Shares
SIG BROKERAGE, LP $4,384,128 93,200 0.11% Call option
Pier Capital, LLC $4,167,650 88,598 0.10% Shares
LPL Financial LLC $4,051,837 86,136 0.10% Shares
Squadron Capital Management LLC $3,998,400 85,000 0.10% Shares

Company insiders 16 insiders · 4 officers · 7 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Schond L. Greenway Chief Financial Officer March 25, 2024 F 211,057 0 0 $0
Miri Halperin Wernli Executive President Aug. 21, 2024 M 202,405 0 0 $0
Carrie Liao Chief Accounting Officer March 25, 2025 S 144,923 0 0 $0
Cynthia W. Hu Chief Legal Officer&Secretary March 24, 2022 A 1,200,000 0 0 $0
Roger Adsett Director June 11, 2026 A 3,555 0 0 $0
Roger Crystal Director June 11, 2026 A 24,289 0 0 $0
Suzanne Louise Bruhn Director June 11, 2026 A 24,289 0 0 $0
Andreas Krebs Director June 11, 2026 A 19,773 0 0 $0
Carol A Vallone Director June 11, 2026 A 21,210 0 0 $0
David W Gryska Director June 11, 2026 A 19,900 0 0 $0
Brigid Makes Director June 1, 2022 A 158,706 0 0 $0
Dan Karlin — Aug. 12, 2026 A 603,282 0 4 $-748,876
Robert Barrow — Aug. 12, 2026 A 1,473,246 0 4 $-2,357,666
Matthew T. Wiley — Aug. 12, 2026 A 237,133 0 1 $-129,101
Brandi Roberts — Aug. 12, 2026 A 271,987 0 1 $-135,675
Mark Sullivan — Aug. 12, 2026 A 383,071 0 4 $-1,041,881

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 34 ETFs

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
PILL · Direxion Shares ETF Trust 1.57% 9,260 NS April 30, 2026 N-PORT
BBC · ETFis Series Trust I 1.29% 21,993 NS April 30, 2026 N-PORT
GSC · Goldman Sachs ETF Trust 0.68% 70,926 NS May 31, 2026 N-PORT
GDOC · Goldman Sachs ETF Trust 0.51% 4,214 NS May 31, 2026 N-PORT
MMSC · First Trust Exchange-Traded Fund VI… 0.44% 9,471 NS May 31, 2026 N-PORT
NUSC · Nushares ETF Trust 0.14% 83,684 NS April 30, 2026 N-PORT
BIB · ProShares Trust 0.12% 3,685 NS May 31, 2026 N-PORT
GSSC · Goldman Sachs ETF Trust 0.08% 31,411 NS May 31, 2026 N-PORT
RSSL · Global X Funds 0.07% 42,629 NS April 30, 2026 N-PORT
ITWO · ProShares Trust 0.06% 4,634 NS May 31, 2026 N-PORT
SCHA · SCHWAB STRATEGIC TRUST 0.05% 473,075 NS May 31, 2026 N-PORT
UWM · ProShares Trust 0.04% 3,624 NS May 31, 2026 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0.03% 37,154 NS April 30, 2026 N-PORT
URTY · ProShares Trust 0.03% 3,665 NS May 31, 2026 N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS 0.01% 3,505 NS May 31, 2026 N-PORT
HDG · ProShares Trust 0.01% 92 NS May 31, 2026 N-PORT
ONEQ · Fidelity Commonwealth Trust 0.01% 40,894 NS May 31, 2026 N-PORT
SCHB · SCHWAB STRATEGIC TRUST 0.00% 55,178 NS May 31, 2026 N-PORT
VXF · VANGUARD INDEX FUNDS — — July 15, 2026 Daily
VFMO · VANGUARD WELLINGTON FUND — — July 30, 2026 Daily
VTWO · VANGUARD SCOTTSDALE FUNDS — — July 15, 2026 Daily
VTWG · VANGUARD SCOTTSDALE FUNDS — — July 15, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS — — July 15, 2026 Daily
ITOT · iShares Trust — — Aug. 3, 2026 Daily
IWV · iShares Trust — — Aug. 18, 2026 Daily
IWO · iShares Trust — — Aug. 18, 2026 Daily
IWM · iShares Trust — — Aug. 18, 2026 Daily
IBB · iShares Trust — — Aug. 18, 2026 Daily
IHE · iShares Trust — — Aug. 18, 2026 Daily
PRFZ · Invesco Exchange-Traded Fund Trust — — July 13, 2026 Daily
VHT · VANGUARD WORLD FUND — — July 20, 2026 Daily
ESML · iShares Trust — — Aug. 14, 2026 Daily
WSML · iShares Trust — — July 20, 2026 Daily
IBBQ · Invesco Exchange-Traded Fund Trust … — — July 20, 2026 Daily